Trial is the first to show a delay in confirmed disability progression in non-relapsing secondary progressive MS

A Cleveland Clinic-led clinical trial of tolebrutinib, an investigational oral Bruton’s tyrosine kinase inhibitor, a group of drugs originally developed to treat lymphomas and related blood disorders, demonstrated a 31% delay in the onset of six-month confirmed disability progression (CDP) in patients with non-relapsing secondary progressive multiple sclerosis (SPMS).

Unexpected lipid drop in obesity could lead to new therapies

New research from Weill Cornell Medicine has uncovered a surprising culprit underlying cardiovascular diseases in obesity and diabetes—not the presence of certain fats, but their suppression. The study, published Feb. 25 in Nature Communications, challenges the conventional belief that a type of fat called ceramides accumulates in blood vessels to cause inflammation and health risks.

FOLOKO PROMISES STRATEGIC FOCUS AFTER RE-ELECTION AS NOCZ PRESIDENT

BARNABAS ZULU INCUMBENT National Olympics Committee of Zambia (NOCZ) President Alfred Foloko who was reelected unopposed has promised to put in place a new strategic direction that will shift the focus of the association. Speaking after being reelected, Foloko reaffirmed his dedication to advancing the goals set out in the NOCZ Strategic Plan 2022–2028. He […]

To continue reading, you must subscribe to either DAILY, WEEKLY or MONTHLY Plans.

Flooding associated with 26% higher hospitalization risk for up to seven months, large-scale study reveals

The world’s largest and most comprehensive study of the long-term health impacts of flooding—via analysis of over 300 million hospitalization records in eight countries prone to flooding events—has found an increased risk of 26% of all diseases serious enough to require hospitalization. This impact on the health of communities lasts up to seven months post event.

Mimicking embryonic growth: Placental IL1α under hypoxia dramatically enhances liver organoid growth

Organoids are made to model human organs and are promising for research and therapy, but there are limitations to their growth and function. A recent study by researchers at The University of Tokyo found that placenta-derived IL1α, under hypoxic conditions, can greatly increase the growth of human stem cell-derived liver organoids. By promoting liver progenitor cell expansion through a specific signaling pathway, this method offers a promising route to improve organoid models and regenerative medicine.